Drugs / OBI-1
OBI-1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00245245 | May 2005 → Jun 2007 | hemophilia A | Octagen Corporation | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01178294 | Nov 2010 → Jul 2013 | acquired hemophilia A | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01434511 | Oct 2011 → Jul 2013 | hemophilia A | Baxalta now part of Shire | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01968655 | — | acquired hemophilia A | Baxalta now part of Shire | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBI-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01968655 ↗ |
| Known as | recombinant porcine coagulation factor VIII | “The ability of a new recombinant porcine coagulation factor VIII, B-domain deleted (called "OBI-1"), to control the non-life- or limb-threatening bleeding episodes patients...” NCT00245245 ↗ |
| Known as | rpFVIII | “BACKGROUND: Recombinant porcine factor VIII (rpFVIII; susoctocog alfa) is indicated for the treatment of bleeding events (BEs) in adults with acquired hemophilia A (AHA).” PMID 39228858 ↗ Sep 2024 |
| Known as | susoctocog alfa | “BACKGROUND: Recombinant porcine factor VIII (rpFVIII; susoctocog alfa) is indicated for the treatment of bleeding events (BEs) in adults with acquired hemophilia A (AHA).” PMID 39228858 ↗ Sep 2024 |
| Modality | Protein / enzyme biologic | “recombinant porcine coagulation factor VIII (OBI-1)” NCT00245245 ↗ |
| Route | Intravenous | “administered intravenously” NCT00245245 ↗ |